<DOC>
	<DOCNO>NCT01172444</DOCNO>
	<brief_summary>An Investigator-Blind , Randomized , Placebo-Controlled , Parallel-Group Study Establish Therapeutic Equivalence 1000 mg Mesalamine Rectal Suppositories Canasa® Rectal Suppositories ( 1000 mg Mesalamine , USP ) Treatment Mild Moderate Ulcerative Proctitis conduct 533 patient estimate duration 18months .</brief_summary>
	<brief_title>Clinical Trial With Mesalamine 1g Suppositories</brief_title>
	<detailed_description />
	<mesh_term>Proctitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>1 . Adults , male female , 18 65 year age 2 . Active , mild moderate UP , disease activity exceed 15 cm beyond anal verge : upper disease boundary confirm flexible sigmoidoscopy/colonoscopy perform within 14 day Baseline Visit 3 . Newly diagnose newly relapse UP , newly relapse UP define UP relapse within less equal 6 week prior Baseline Visit 4 . A Disease Activity Index ( DAI ) score great equal 4 less equal 10 Baseline Visit ; DAI must include Physician 's Global Assessment ( PGA ) subscore less equal 2 , rectal bleeding subscore great equal 1 mucosal appearance subscore great equal 1 5 . Histological confirmation UP Histological Disease Activity Score &gt; equal 1 biopsy take severe area disease flexible sigmoidoscopy/colonoscopy perform within 14 day Baseline Visit 6 . For female patient childbearing potential , negative serum pregnancy test Screening Visit negative urine pregnancy test Baseline Visit ; female patient consider childbearing potential unless postmenopausal least one year surgically sterilize ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) 7 . Female patient childbearing potential must practice one follow method birth control must agree continue regimen throughout study : hormonal method oral , implantable , injectable , transdermal contraceptive minimum one full cycle ( base patient 's usual menstrual cycle period ) investigational product administration ; total abstinence sexual intercourse ( since last menses investigational product administration ) ; intrauterine device ; double barrier method ( condom , sponge , diaphragm , vaginal ring spermicidal jelly cream ) ; Male patient must also agree use acceptable method birth control female partner , may include use male condom plus spermicide . 8 . Ability give write informed consent 9 . Ability willingness comply study requirement , include dosing procedure , diary completion , study visit 1 . Known history allergic reaction clinically significant intolerance aspirin salicylate derivative ( include mesalamine ) nonactive ingredient investigational product 2 . Onset UP relapse &gt; 6 week prior Baseline Visit patient experience relapse UP ( i.e. , patient newly diagnose ) 3 . Severe UP defined DAI score great equal 11 PGA subscore 3 4 . Histological Disease Activity Score &gt; equal 1 biopsy take normal tissue disease margin flexible sigmoidoscopy/colonoscopy perform within 14 day Baseline Visit 5 . UP disease involvement great 15 cm beyond anal verge confirm flexible sigmoidoscopy/colonoscopy 6 . Prior unsuccessful treatment active UP active ulcerative colitis rectally administer mesalamine preparation strength 7 . Any prior treatment UP ulcerative colitis oral 5aminosalicylic acid product use &gt; 2 g/day , regardless treatment outcome 8 . Use local , rectally administer therapy UP ulcerative colitis ( e.g. , suppository enemas contain mesalamine , etc . ) within 30 day Baseline Visit 9 . Use following medication : Biological therapy ( e.g. , infliximab ) within 90 day Baseline Visit Immunosuppressive/immunomodulating ( e.g. , azathioprine ) medication within 90 day Baseline Visit Oral , intravenous , intramuscular , rectally administer corticosteroid within 30 day Baseline Visit ; use intranasal and/or inhale corticosteroid permit Oral 5aminosalicylic acid product within 7 day Baseline Visit , use &amp; less equal 2 g/day Oral , intravenous , intramuscular antibiotic within 7 day Baseline Visit NonSteroidal AntiInflammatory Drugs ( NSAIDs ) within 7 day Baseline Visit ; lowdose aspirin ( less equal 325 mg/day ) take cardioprotective reason permit Antidiarrheals , antispasmodic , iron therapy within 7 day Baseline Visit Transdermal nicotine product within 7 day Baseline Visit 10 . A change regimen ( i.e. , dosage frequency use ) permit medication within 30 day Baseline Visit , plan change regimen course study 11 . Use treatment investigational drug , therapy , device within 30 day Baseline Visit 12 . A planned change tobacco usage ( e.g. , smoking , oral tobacco ) study 13 . Female patient pregnant , planning pregnancy , breastfeed 14 . Diseases interfere DAI assessment , include limited , hemorrhoids anal fissure 15 . History Crohn Disease , short bowel syndrome , bowel surgery ( except appendectomy ) , active peptic ulcer 16 . A positive stool culture enteric pathogen ( Salmonella , Shigella , Yersinia , Campylobacter , Vibrio , E. coli O157/H7 ) , detection Clostridium difficile toxin immunoassay , enteric parasite ova ( include Giardia , Cryptosporidium , Entamoeba histolytica ) routine microscopy Screening Visit 17 . Significant impairment renal hepatic function , define follow : Creatinine &gt; 1.5 x Upper Limit Normal ( ULN ) Alanine Amino Transferase ( ALT ) &gt; 2.5 x ULN Aspartate Amino Transferase ( AST ) &gt; 2.5 x ULN 18 . Serologic positivity Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) , Human Immunodeficiency Virus ( HIV ) , Treponema pallidum ( causative agent syphilis ) 19 . Known history idiopathic / chronic pancreatitis 20 . History active drug alcohol abuse within past year , physical examination finding indicate 21 . Current clinically significant urinary tract obstruction 22 . History coagulation disorder , include require treatment anticoagulant drug ( except aspirin take ≤325 mg/day cardioprotective reason 23 . Current active malignancy history malignancy within past five year , except cervical carcinoma situ , squamous basal cell carcinoma skin surgically remove , prostate cancer manage watchful waiting ( observation alone ) 24 . History pelvic irradiation 25 . Any clinically significant abnormal medical condition Investigators judgment would put patient increase risk illness injury , would interfere study participation would interfere evaluation quality data 26 . Inability unwillingness understand comply requirement protocol reason , include dose procedure visit requirement 27 . Previous randomization study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Mild Moderate Ulcerative Proctitis</keyword>
</DOC>